Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) is a clinical-stage leader developing TCR-T cell therapies targeting neoantigens in solid tumors. This page provides centralized access to all material updates from this innovator in precision immuno-oncology.
Investors and researchers will find essential announcements including clinical trial progress, regulatory milestones, and scientific collaborations. Our curated feed ensures timely access to verified updates on therapeutic developments and corporate strategy.
Key content areas include updates on TCR-T platform advancements, partnership announcements with research institutions, and financial disclosures. All information is sourced directly from company filings and authorized communications.
Bookmark this page for efficient tracking of Alaunos' pioneering work in targeting RAS-mutant cancers and other genomic drivers. Check regularly for developments in their mission to transform solid tumor treatment through engineered cellular therapies.
Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.
Alaunos Therapeutics (Nasdaq: TCRT) announced the appointment of Robert J. Hofmeister, PhD, as Chief Scientific Officer of the Board of Directors, effective immediately. Hofmeister replaces Chris Bowden, MD. With over 25 years of expertise in T-cell therapy, Hofmeister previously led scientific teams at TCR2 Therapeutics and played a crucial role in developing their TRuC®-T cell platform. Alaunos aims to advance its TCR-T Library Phase 1/2 trial targeting solid tumors. The company benefits from its proprietary Sleeping Beauty cell engineering platform and industry-leading library of TCRs. The ongoing collaboration with the National Cancer Institute supports its research and development efforts.
Alaunos Therapeutics (Nasdaq: TCRT), a prominent T-cell receptor cell therapy company, announced its participation in two upcoming investor conferences. The first is Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, featuring fireside chats and one-on-one meetings. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, which will include a company presentation and one-on-one meetings. A live webcast of the Needham presentation will be available on Alaunos' website for 90 days post-event. Alaunos is advancing TCR therapies for solid tumors and collaborates with the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced transformative advancements in TCR-T cell therapy for solid tumors, showcasing promising clinical results. The company successfully enrolled patients in its TCR-T Library Phase 1/2 trial, with expectations to report interim data by mid-2023. Its TCR library has doubled, integrating new TCRs that enhance market reach. Manufacturing efficiency has improved, decreasing processing times by 13%. Financially, Alaunos reported a net loss of $9.2 million for Q4 2022, down from $11.8 million year-over-year. With $53 million in cash reserves, the company anticipates sufficient funding into Q4 2023.
